Rubric Capital Management LP Incyte Corp Transaction History

Rubric Capital Management LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 10, 2019	SELL	$63.56 - $88.17 $42.9 Million - $59.5 Million	-675,000 Closed	0 $0
Q4 2018 Feb 13, 2019	SELL	$58.5 - $69.94 $7 Million - $8.37 Million	-119,640 Reduced 15.06%	675,000 $42.9 Million
Q3 2018 Nov 13, 2018	BUY	$61.75 - $74.23 $49.1 Million - $59 Million	794,640 New	794,640 $54.9 Million

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.7B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Rubric Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Rubric Capital Management LP with notifications on news.